IK acquires ZytoService from Capiton
IK Investment Partners (“IK”) is pleased to announce that the IK VIII Fund has reached an agreement to acquire ZytoService Group (“ZytoService” or “the Company”), a leading compounder of pharmaceuticals for patient-individualised infusions, from the founders and Capiton. Financial terms of the transaction are not disclosed.
Founded in 2002, ZytoService is one of the largest industrially organised §13 AMG (‘Arzneimittelgesetz’) certified compounders for patient-individualised infusions applied mainly in oncology treatment in Germany. The Company is based in Hamburg, where it runs a state-of-the-art compounding facility.
“We are delighted to be working with IK going forward. ZytoService operates in an industry in which IK has extensive expertise, and with their support we will be well placed to further expand our competence and provide the best service to our customers,” said Enno Scheel, Co-Founder of ZytoService.
“We firmly believe in the strengths of partnering with IK. Together, we will continue investing in the business to better address the growing demands of the German healthcare market,” added Thomas Boner, Co-Founder of ZytoService.
Mr Enno Scheel and Mr Thomas Boner, Co-Founders and Co-CEOs of ZytoService will remain with the business in managerial roles, and will be shareholders alongside IK.
“Thanks to IK’s experience in the relevant sector, we quickly recognised ZytoService’s potential. We look forward to backing the management team and expanding the Company’s operational capabilities. We believe ZytoService is ideally positioned to develop further and provide highest quality services to its customers,” said Detlef Dinsel, Managing Partner at IK and advisor to the IK VIII Fund.
Completion of the transaction is subject to custom legal and regulatory approvals.
ZytoService will be the second investment of the 2016 established IK VIII Fund.
ZytoService operates as a leading compounder of patient-individualised infusions, specialising mainly on the field of oncology. The Company conducts its compounding operations at a state-of-the art facility located in Hamburg, in accordance with §13 AMG (‘Arzneimittelgesetz’) regulation.
Source: IK Investment Partners Press Release